Conference Reports for NATAP
The Liver Meeting
San Francisco
November 2018
Back
 
Effectiveness of Sofosbuvir/Velpatasvir for 12 Weeks in HCV Genotype 3 Patients with Compensated Cirrhosis in Clinical Practice Cohorts from Around the World
Reported by Jules Levin
AASLD 2018 Nov 9-12 Boston